Geniposide prevents rotenone-induced apoptosis in primary cultured neurons

Lin Li¹, Juan Zhao¹, Ke Liu¹, Guang-lai Li², Yan-qing Han², Yue-ze Liu¹*†

1 Key Laboratory of Cellular Physiology, Shanxi Medical University, Taiyuan, Shanxi Province, China
2 Second Hospital, Shanxi Medical University, Taiyuan, Shanxi Province, China

Abstract

Geniposide, a monomer extracted from gardenia and widely used in Chinese medicine, is a novel agonist at the glucagon-like peptide-1 receptor. This receptor is involved in neuroprotection. In the present study, we sought to identify an anti-apoptotic mechanism for the treatment of neurodegenerative diseases. Primary cultured neurons were treated with different concentrations of rotenone for 48 hours. Morphological observation, cell counting kit-8 assay, lactate dehydrogenase detection and western blot assay demonstrated that 0.5 mM rotenone increased lactate dehydrogenase release, decreased the expression of procaspase-3 and Bcl-2, and increased cleaved caspase-3 expression in normal neurons. All these effects were prevented by geniposide. Our results indicate that geniposide diminished rotenone-induced injury in primary neurons by suppressing apoptosis. This may be one of the molecular mechanisms underlying the efficacy of geniposide in the treatment of neurodegenerative diseases.

Key Words: nerve regeneration; geniposide; rotenone; cell apoptosis; Alzheimer’s disease; caspase-3; Bcl-2; neural regeneration

Funding: This research was supported by grants from the Shanxi Science and Technology Department in China, No. 2011081060 and Shanxi Scholarship Council of China, No. 2011-44.

Li L, Zhao J, Liu K, Li GL, Han YQ, Liu YZ (2015) Geniposide prevents rotenone-induced apoptosis in primary cultured neurons. Neural Regen Res 10(10):1617-1621.

Introduction

There are a number of similarities between the pathologies of diabetes and Alzheimer’s disease, indicating that the diseases should respond to similar treatment (Li and Hölsccher, 2007). The protective effect of glucagon-like peptide (GLP)-1 on the brain has been shown in vitro (Wang et al., 2013) and in vivo (Li et al., 2012), and GLP-1 analogues have been used to treat diabetes since 2005 (Lin, 2008). Geniposide is a major active ingredient in the fruits of Gardenia jasminoides Ellis (Wang et al., 2014), which is known for its antioxidant (Koo et al., 2004), anti-inflammatory (Koo et al., 2006), antithrombotic (Suzuki et al., 2001), immunosuppressant (Chang et al., 2005), neuroprotective (Liu et al., 2009), and hypoglycemic (Kojima et al., 2011) properties. Using high throughput screening, Liu et al. (2006) confirmed that geniposide is an agonist for GLP-1 receptor.

A number of studies have focused on the neuroprotective action of geniposide. Liu et al. (2007, 2009) explored this in PC12 cells and showed that it regulates the expression of anti-oxidant proteins such as heme oxygenase-1 (HO-1) and Bcl-2 by activating the transcription factor p90RSK via the mitogen-activated protein kinase signaling pathway. The same report also implicated the phosphatidylinositol 3-kinase signaling pathway in the neuroprotective effect of geniposide against the oxidative damage induced by H₂O₂. Similarly, geniposide was shown to protect PC12 cells from CoCl₂ in mitochondria-mediated apoptosis (Guo et al., 2009) and from oxidative damage induced by 3-morpholinosydnonimine hydrochloride, by enhancing the expression of heme oxygenase 1 via the cyclic adenosine monophosphate-protein kinase A-response element binding protein signaling pathway (Yin et al., 2010). Geniposide activates the GLP-1 receptor and protects against β-amyloid-induced neurotoxicity, regulating the expression of insulin-degrading enzyme in cortical neurons (Yin et al., 2012). The molecule can also protect SH-SYSY cells against formaldehyde stress by modulating the expression of Bcl-2, P53, caspase 3 and caspase 9, and by increasing the activity of intracellular superoxide dismutase and glutathione peroxidase (Sun et al., 2013). It is unclear whether anti-apoptosis is one of the molecular mechanisms by which geniposide exerts a protective effect against neurodegenerative disease. Here, we investigated this hypothesis by exploring whether geniposide prevents rotenone-induced apoptosis in primary cultured neurons.

Materials and Methods

Animals

Swiss mouse pups (1–3 days old) were obtained from the Animal Center at Shanxi Medical University in China (license No. SCXK (Jin) 2009-0001). All animal procedures were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (National Institutes of Health Publications, No. 80–23, revised 1978) and approved by the Animal Ethics Committee in Shanxi
Medical University in China.

**Primary culture of mouse neurons**
Tissue preparation was performed on ice. Neonatal mice were sacrificed by decapitation. Cortical and hippocampal tissues were isolated and washed in Ca\(^{2+}\) - and Mg\(^{2+}\)-free Hanks balanced salt solution. The tissue was cut into small pieces and incubated with 0.25% trypsin for 10 minutes at 37°C. The trypsin was inactivated using fetal bovine serum to prevent excessive dissociation. The dissolved tissues were centrifuged at 1,000 r/min for 5 minutes, and the cells were taken and cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum, 1% penicillin and streptomycin (Trans, Beijing, China) in a humidified atmosphere at 37°C, 5% CO\(_2\), for 6 hours. They were then transferred to neurobasal medium (Gibco, Carlsbad, CA, USA) containing 2% B27 supplement, 1% L-glutamine and 1% penicillin and streptomycin. Neurons were cultured and grown for 7 days until they reached 70–80% confluence.

**Estimation of effective rotenone concentration by cell counting kit-8 (CCK-8) assay**
Primary neuronal cells were seeded in 96-well cell culture plates (1 × 10\(^5\) cells per well) at 37°C for 7 days. Cells were incubated with various concentrations of rotenone (0.5, 1, 3, and 5 nM; Solarbio, Beijing, China) for 2 days, to identify the lowest concentration at which cellular survival was inhibited. CCK-8 solution (10 µL per well; Dojindo Laboratories, Tokyo, Japan) was added directly to the cell suspension and followed by a 2-hour incubation at 37°C. Cell morphology was observed under a light microscope (Olympus, Tokyo, Japan). Optical density was measured at 450 nm using a microplate reader (Bio-Rad, Hercules, CA, USA).

**Estimation of geniposide concentrations that offer protection for cultured neurons by lactate dehydrogenase (LDH) assay**
Cultured neurons were incubated for 7 days, then pre-treated with various concentrations of geniposide in normal saline (0, 10, 50, 100, and 200 µM; Marker Inc., Tianjin, China), to identify the optimal neuroprotective concentration after 2 hours of incubation. Neurons were then exposed to rotenone (0.5 nM) for 48 hours. The viability of cultured neurons was measured by LDH assay ( Jiancheng Company, Nanjing, Jiangsu Province, China), according to the manufacturer’s instructions. LDH activity was quantified by measuring optical density at a wavelength of 440 nm with a 722 Visible Spectrophotometer (Shanghai Optical Instrument Factory, Shanghai, China). Released LDH activity was expressed as a percentage of total LDH activity, which was determined after freeze-thaw lysis of the cells.

**Western blot assay of apoptotic signaling protein levels in neurons**
After incubation for 7 days, cultured neurons were pre-treated with geniposide (50 µM) for 2 hours followed by rotenone (0.5 nM) for 48 hours. The expression of apoptosis-related proteins (procaspase-3, cleaved caspase-3 and Bcl-2) in the neurons was measured by western blot assay. Cells were plated in culture dishes at a concentration of 1 × 10\(^4\) cells per dish, and grown for 7 days until they reached 70–80% confluence. They were then collected in ice-cold radio-immunoprecipitation assay buffer (containing Tris pH 7.4, NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% sodium dodecyl sulphate, 5 mM ethylenediamine tetraacetic acid, 1 mM sodium orthovanadate, 10 mM sodium fluoride) and 1 nM phenylmethylsulfonyl fluoride (Beyotime Company, Shanghai, China). Samples were centrifuged at 12,000 r/min for 5 minutes at 4°C, and the supernatant was taken. The concentration of total cell proteins was determined using the Bicinchoninic Acid Protein Assay kit (Beyotime Company). Equal volumes of loading buffer were added to each sample. Samples (30 µg protein) were run in a 15% Tris-Tricine gel and transferred electrophoretically onto polyvinylidene difluoride membranes. The membranes were blocked with 5% bovine serum albumin in phosphate buffered saline supplemented with 0.05% Tween-20 at room temperature for 2 hours, and then incubated overnight with rabbit anti-pro-caspase-3 polyclonal antibody (1:500; Abcam, Cambridge, UK), rabbit anti-cleaved caspase-3 polyclonal antibody (1:1,000; Cell Signaling Technology, Boston, MA, USA), rabbit anti-Bcl-2 polyclonal antibody (1:500; Abcam) and rabbit anti-rat β-actin monoclonal antibody (1:500; Abcam). After washing with phosphate buffered saline supplemented with Tween 20, the membranes were incubated with goat anti-rabbit IgG-horseradish peroxidase (1:5,000; Abcam) for 2 hours at room temperature. The bands were visualized using the enhanced chemiluminescence system (Transgen, Beijing, China). The relative amounts of proteins on the blots were scanned and quantified using ImageJ software (National Institutes of Health, Bethesda, MD, USA), which was used to count relative optical density: a optical density ratio of target protein to β-actin.

**Statistical analysis**
All data were expressed as the mean ± SEM. Differences between groups were assessed by one-way analysis of variance. Dunnett’s t-test was used for pairwise comparison between groups. Statistical analyses were performed using SPSS 16.0 software (SPSS, Chicago, IL, USA) and displayed using Prism 5 (GraphPad Software Inc., La Jolla, CA, USA). All experiments were performed independently in triplicate. \(P < 0.05\) was considered statistically significant.

**Results**
**Neurotoxicity induced by rotenone in primary cultured neurons**
Evident morphological changes such as cell loss, shrinkage, intensification of refraction, floatation, and string-of-beads appearance were seen in the cultured hippocampal and cortical neurons exposed to rotenone (5 nM) for 48 hours, compared with control cells. The CCK-8 assay showed that different concentrations of rotenone decreased the number of cultured neurons in a dose-dependent manner \(P < 0.01\).
or $P < 0.05$). The lowest concentration that induced changes in cellular viability was 0.5 nM (Figure 1).

**LDH release in cultured neurons treated with different concentrations of geniposide**

Geniposide did not induce a significant change in the percentage of total LDH activity at any concentration compared with the control group ($P > 0.05$; Figure 2).

**Protective effect of geniposide against rotenone toxicity**

Release of LDH was significantly greater in cultured neurons exposed to 0.5 nM rotenone than in control neurons ($P < 0.01$). This increase was prevented by pretreatment with different concentrations of geniposide ($P < 0.01$; Figure 3).

**Geniposide inhibited apoptotic signals induced by rotenone**

Western blot assay revealed that procaspase-3 was decreased and cleaved caspase-3 was increased 48 hours after exposure to rotenone (0.5 nM) ($P < 0.01$). These effects were prevented by pretreatment with 50 µM geniposide ($P < 0.01$ or $P < 0.05$ vs. rotenone). The rotenone-induced decrease in Bcl-2 expression was also prevented by pretreatment with 50 µM geniposide ($P < 0.05$). No significant differences were observed between control and 50 µM geniposide-treated neurons in any of the three proteins ($P > 0.05$; Figure 4).

**Discussion**

The complexity of Chinese medicine results, in part, from the fact that a single Chinese herb may contain a large number of compounds, among which are the key component(s) and the effective monomer(s). Each of these compounds may interact, making it difficult to identify the specific actions of each component. An increasing number of studies indicate that the pharmacokinetics and therapeutic effects of a monomer differ between its pure form and when it is part of the herbal extract. Geniposide, a monomer extracted from *Gardenia jasminoides Ellis*, has an extensive range of biological effects, and interest in its molecular mechanism is growing. GLP-1 is neuroprotective and activates the GLP-1 receptor in the brain (Gao et al., 2014). Using high throughput screening, Liu et al. (2006) identified geniposide as a novel agonist at this receptor. We therefore hypothesized that geniposide exerts its neuroprotective effects by acting at brain GLP-1 receptors. Geniposide has been suggested as a treatment for Alzheimer’s and Parkinson’s diseases. Our previous study indicated that geniposide may exert its neuroprotective effect by the PI3K signaling pathway after activating the GLP-1 receptor in the brain (Gao et al., 2014). In the present study, we have demonstrated the anti-apoptotic and neuroprotective effect of geniposide in cultured neurons. Excessive neuronal apoptosis leads to a variety of diseases including Alzheimer’s and Parkinson’s diseases (Taylor et al., 2008). In *vitro* and *in vivo* studies of Parkinson’s disease models have revealed that rotenone induces Parkinson’s disease-like behavioral and neuropathological changes, including the induction of apoptosis and acceleration of α-synuclein formation (Bové et al., 2005; Olanow, 2007).

As a mitochondrial complex I inhibitor, rotenone exposure may mimic certain aspects of Parkinson’s disease. Non-familial (sporadic) Parkinson’s disease is characterized by a 15–30% reduction in mitochondrial complex I activity. Neurodegenerative processes involving aggregation of β-amyloid and hyperphosphorylated tau are often coupled with impairment of mitochondrial complex I. Similarly, rotenone induces β-amyloid aggregation, as well as increasing tau hyperphosphorylation (Chaves, 2010). In the present study, we established a cellular model of neuronal apoptosis using rotenone-treated primary cultured neurons, to test the hypothesis that geniposide may protect neurons from apoptosis in neurodegenerative diseases. Rotenone is a naturally occurring organic pesticide known to inhibit complex I of the mitochondrial electron transport chain (Hartley et al., 1994). Epidemiological studies have suggested a positive correlation between rotenone exposure and Parkinson’s disease in human populations (Tanner et al., 2011). Furthermore, chronic rotenone exposure induces a Parkinsonian phenotype in rodents (Cannon et al., 2009). Rotenone can induce the formation of reactive oxygen species, indicating a potential mechanistic link between oxidative stress and Parkinson’s disease (Li et al., 2003). In addition, rotenone was used to induce neurodegenerative disease in cultured neurons (Worth et al., 2014).

Our findings indicate that rotenone-induced apoptosis is associated with the expression and activation of caspase-3 and Bcl-2. Caspase-3 is considered to be the central protein in the execution of apoptosis, and its activated form (cleaved caspase-3) is a valuable tool by which to identify apoptotic cells, even before the morphological features of apoptosis are present. Many proteins contribute to the regulation of apoptosis; among them, there are the Bcl-2 family proteins, which include proapoptotic proteins such as Bax, and anti-apoptotic proteins such as Bcl-2 and Bcl-xL (Cunha et al., 2013). The present study shows that geniposide pretreatment inhibits the expression of cleaved caspase-3 and prevents the reduction in procaspase-3 induced by rotenone. Bcl-2 preserves mitochondrial integrity by preventing loss of mitochondrial membrane potential and/or release of pro-apoptotic proteins such as cytochrome C into the cytosol (Harada and Grant, 2003). Our data suggest that geniposide prevents rotenone-induced downregulation of Bcl-2.

In conclusion, the GLP-1 receptor agonist geniposide protects cultured neurons from rotenone-induced damage. This may be one of the molecular mechanisms underlying the action of geniposide, and our results suggest that GLP-1 may be a promising novel target in the treatment of neurodegenerative diseases.

**Author contributions:** LL and YZL were responsible for the study proposal, design, grant support and wrote the paper. GLL analyzed western blot assay. JZ and KL performed all of experimental process. YQH determined the survival of cultured neurons. All authors approved the final version of the paper.

**Conflicts of interest:** None declared.
Figure 1 Survival of cultured neurons treated with various concentrations of rotenone.
(A, B) Hippocampal and cortical control (A) and rotenone-treated (B) neurons. There were notably fewer neurons after rotenone (5 nM) exposure (optical microscopy). Scale bar: 500 µm. (C) Cell viability was analyzed using CCK-8 assay. Optical density (OD) of control group was set to 100% and the data were normalized to control group. Experiments were performed in triplicate. Neurons were incubated for 7 days before exposure to rotenone (0, 0.5, 1, 3, 5 nM) for 48 hours in the culture medium. Data are expressed as the mean ± SEM. Differences between groups were assessed by one-way analysis of variance. Dunnett’s t-test pairwise comparison was used to compare groups. *P < 0.05, **P < 0.01, vs. control neurons; #P < 0.05, vs. 0.5 nM rotenone treated neurons.

Figure 2 LDH release in cultured neurons treated by different concentrations of geniposide.
Data are expressed as the mean ± SEM. Differences between groups were assessed by one-way analysis of variance. Dunnett’s t-test was used for pairwise comparison between groups. *P < 0.05, **P < 0.01, vs. control neurons; #P < 0.05, ##P < 0.01, vs. 0.5 nM rotenone-treated neurons. LDH: Lactate dehydrogenase.

Figure 3 Effects of geniposide on LDH release in rotenone-treated neurons.
Data are expressed as the mean ± SEM. Differences between groups were assessed by one-way analysis of variance. Dunnett’s t-test was used for pairwise comparison between groups. **P < 0.01, vs. control neurons; #P < 0.05, ##P < 0.01, vs. 0.5 nM rotenone-treated neurons. Geniposide inhibited rotenone-induced LDH release. Ge: Geniposide; LDH: lactate dehydrogenase.

Figure 4 Effects of geniposide (50 µM) on apoptosis-related protein expression in rotenone-treated neurons (western blot assay).
(A) Procaspase-3, (B) cleaved caspase-3, (C) Bcl-2. Lane 1: Control; lane 2: 0.5 nM rotenone; lane 3: 50 µM geniposide; lane 4: 50 µM geniposide pretreatment and 0.5 nM rotenone. The optical density ratio of target protein to β-actin protein was determined. Data are expressed as the mean ± SEM. Differences between groups were assessed by one-way analysis of variance. Dunnett’s t-test was used for pairwise comparison between groups. *P < 0.05, **P < 0.01, vs. control neurons; #P < 0.05, ##P < 0.01, vs. 0.5 nM Ro-treated neurons. Ro: Rotenone; Ge: geniposide.
References
Bové J, Prou D, Perier C, Przedborski S (2005) Toxin-induced models of Parkinson's disease. NeuroRx 2:484-494.

Cannon JR, Tapia V, Na HM, Honick AS, Drolet RE, Greenamyre JT (2009) A highly reproducible rotenone model of Parkinson's disease. Neurobiol Dis 34:279-290.

Chang WL, Wang HY, Shi LS, Lai JH, Lin HC (2005) Immunosuppressive Iridesoids from the Fruits of Gardenia jasminoides. J Nat Prod 68:1683-1685.

Cunha KS, Caruso AC, Faria PA, Silva LED, Fonseca ECD, Geller M, de Moura-Neto RS, Lopes VS (2013) Evaluation of Bcl-2, Bcl-x and cleaved caspase-3 in malignant peripheral nerve sheath tumors and neurofibromas. An Acad Bras Cienc 85:1497-1511.

Gao C, Holscher C, Liu Y, Li L (2011) GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer's disease. Rev Neurosci 22:1-11.

Gao C, Liu Y, Jiang Y, Ding J, Li L (2014) Geniposide ameliorates learning memory deficits, reduces tau phosphorylation and decreases apoptosis via GSK3β pathway in streptozotocin-induced Alzheimer rat model. Brain Pathol 24:261-269.

Guo LX, Liu JH, Xia ZN (2009) Geniposide inhibits CoCl2-induced PC12 cells death via the mitochondrial pathway. Chin Med J (Engl) 122:2886-2892.

Harada H, Grant S (2003) Apoptosis regulators. Rev Clin Exp Hematol 7:117-138.

Hartley A, Stone JM, Heron C, Cooper JM, Schapira AHV (1994) Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: relevance to Parkinson's disease. J Neurochem 63:1987-1990.

Kojima K, Shimada T, Nagareda Y, Watanabe M, Ishizaki J, Sai Y, Miyamoto K-I, Aburada M (2011) Preventive effect of geniposide on metabolic disease status in spontaneously obese type 2 diabetic mice and free fatty acid-treated HepG2 cells. Biol Pharm Bull 34:1613-1618.

Koo HJ, Lim KH, Jung HJ, Park EH (2006) Anti-inflammatory evaluation of gardenia extract, geniposide and genipin. J Ethnopharmacol 103:496-500.

Koo HJ, Lee S, Shin KH, Kim BC, Lim CJ, Park EH (2004) Geniposide, an anti-angiogenic compound from the fruits of Gardenia jasminoides. Planta Med 70:467-469.

Li L, Holscher C (2007) Common pathological processes in Alzheimer disease and type 2 diabetes: A review. Brain Res Rev 56:384-402.

Li L, Zhang ZF, Holscher C, Gao C, Jiang YH, Liu YZ (2012) (Val8)-glucagon-like peptide-1 prevents tau hyperphosphorylation, impairment of spatial learning and ultra-structural cellular damage induced by streptozotocin in rat brains. Eur J Pharmacol 674:280-286.

Li N, Bagheh K, Lawger G, Sturgis J, Rajwa B, Melendez JA, Robinson JP (2003) Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J Biol Chem 278:8516-8525.

Lin L (2008) Commonality between diabetes and Alzheimer's disease and a new strategy for the therapy. Clin Med Pathol 1:83-91.

Liu J, Yin F, Zheng X, JIng J, Hu Y (2007) Geniposide, a novel agonist for GLP-1 receptor, prevents PC12 cells from oxidative damage via MAP kinase pathway. Neurochem Int 51:361-369.

Liu J, Zhang X, Yin F, Hu Y, Guo L, Deng X, Chen G, Jiajia J, Zhang H (2006) Neurotrophic property of geniposide for inducing the neuronal differentiation of PC12 cells. Int J Dev Neurosci 24:419-424.

Liu JH, Yin F, Guo LX, Deng XH, Hu YH (2009) Neuroprotection of geniposide against hydrogen peroxide induced PC12 cells injury: involvement of PI3 kinase signal pathway. Acta Pharmacol Sin 30:159-165.

Olanow CW (2007) The pathogenesis of cell death in Parkinson's disease – 2007. Mov Disord 22:5335-S342.

Sun P, Chen YJ, Li L, Sun MR, Mo WC, Liu KL, Meng YY, Li Y, Wang F, He BQ, Hua Q (2013) The protective effect of geniposide on human neuroblastoma cells in the presence of formaldehyde. BMC Complement Altern Med 13:152.

Suzuki Y, Kondo K, Ikeda Y, Umemura K (2001) Anti-thrombotic effect of geniposide and genipin in the mouse thrombosis model. Planta Med 67:807-810.

Taylor RC, Cullen SP, Martin SJ (2008) Apoptosis: controlled demolition. Environ Health Perspect 116:866-872.

Taylor RC, Cullen SP, Martin SJ (2008) Apoptosis: controlled demolition. Environ Health Perspect 119:866-872.

Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, Marras C, Bhudhikanok GS, Kesten M, Chade AR, Comyns K, Richards MB, Meng C, Priestley B, Fernandez EH, Cambi F, Umbach DM, Blair A, Sandler DP, Langston JW (2011) Rotenone, paraquat, and Parkinson's disease. Environ Health Perspect 119:866-872.

Taylor RC, Cullen SP, Martin SJ (2008) Apoptosis: controlled demolition. Environ Health Perspect 119:866-872.

Wang F, Cao J, Hao J, Liu K (2014) Pharmacokinetics, bioavailability and tissue distribution of geniposide following intravenous and peroral administration to rats. Biopharm Drug Dispos 35:97-103.

Wang XH, Yang W, Holscher C, Wang ZJ, Cai HY, Li QS, Qi JS (2013) Val8-GLP-1 remodels synaptic activity and intracellular calcium homeostasis impaired by amyloid β peptide in rats. J Neurosci Res 91:568-577.

Worth AJ, Basu SS, Snyder NW, Mesaros C, Blair IA (2014) Inhibition of neuronal cell mitochondrial complex I with rotenone increases lipid β-oxidation, supporting acetyl-coenzyme A levels. J Biol Chem 289:26895-26903.

Yin F, Liu JH, Zheng XX, Guo LX (2010) GLP-1 receptor plays a critical role in geniposide-induced expression of heme oxygenase-1 in PC12 cells. Acta Pharmacol Sin 31:540-545.

Yin F, Zhang Y, Guo L, Kong S, Liu J (2012) Geniposide regulates insulin-degrading enzyme expression to inhibit the cytotoxicity of Aβ42 in cortical neurons. CNS Neurol Disord Drug Targets 11:1045-1051.

Copyedited by Slone-Murphy J, de Souza M, Yi J, Qiu Y, Li CH, Seng LP.
Zhao M